Antioxidant agents for delaying diabetic kidney disease progression: A systematic review and meta-analysis.

Davide Bolignano,Rossella Baggetta,Guido Gembillo,Valeria Cernaro,Graziella D'Arrigo,Michele Buemi,Gianpaolo Reboldi

doi:10.1371/journal.pone.0178699

Davide Bolignano, Rossella Baggetta + Show 5 more

Open Access

https://doi.org/10.1371/journal.pone.0178699

Copy DOI

Journal: PloS one	Publication Date: Jun 1, 2017
Citations: 88	License type: CC BY 4.0

Affiliation: Istituto di Fisiologia Clinica, University of Messina

Abstract

BackgroundOxidative stress is a key player in the genesis and worsening of diabetic kidney disease (DKD). We aimed at collecting all available information on possible benefits of chronic antioxidant supplementations on DKD progression.Study designSystematic review and meta-analysis.PopulationAdults with DKD (either secondary to type 1 or 2 diabetes mellitus)Search strategy and sourcesCochrane CENTRAL, Ovid-MEDLINE and PubMed were searched for randomized controlled trials (RCTs) or quasi-RCTs without language or follow-up restriction.InterventionAny antioxidant supplementation (including but not limited to vitamin A, vitamin C, vitamin E, selenium, zinc, methionine or ubiquinone) alone or in combination.OutcomesPrimary outcome was progression to end-stage kidney disease (ESKD). Secondary outcomes were change in albuminuria, proteinuria, serum creatinine and renal function.ResultsFrom 13519 potentially relevant citations retrieved, 15 articles referring to 14 full studies (4345 participants) met the inclusion criteria. Antioxidant treatment significantly decreased albuminuria as compared to control (8 studies, 327 participants; SMD: -0.47; 95% CI -0.78, -0.16) but had apparently no tangible effects on renal function (GFR) (3 studies, 85 participants; MD -0.12 ml/min/1.73m2; 95% CI -0.06, 0.01). Evidence of benefits on the other outcomes of interest was inconclusive or lacking.LimitationsSmall sample size and limited number of studies. Scarce information available on hard endpoints (ESKD). High heterogeneity among studies with respect to DKD severity, type and duration of antioxidant therapy.ConclusionsIn DKD patients, antioxidants may improve early renal damage. Future studies targeting hard endpoints and with longer follow-up and larger sample size are needed to confirm the usefulness of these agents for retarding DKD progression.

Highlights

Diabetes Mellitus (DM) remains one of the most challenging global epidemics of the twentyfirst century
Future studies targeting hard endpoints and with longer follow-up and larger sample size are needed to confirm the usefulness of these agents for retarding diabetic kidney disease (DKD) progression
We included any randomized controlled trial (RCT) and quasi-randomized controlled trials (RCTs) testing the effects of any antioxidant supplementation on renal endpoints in patients with diabetic kidney disease (DKD)

Summary

Introduction

Diabetes Mellitus (DM) remains one of the most challenging global epidemics of the twentyfirst century. Progressive impairment in renal function is associated with an increased risk of cardiovascular events and hospitalizations, in ESKD patients needing chronic renal replacement therapy by dialysis or kidney transplantation. Sparse evidence has accrued indicating that antioxidant supplements may bring significant benefits to DKD patients, including the reduction of urinary albumin and total protein excretion and the normalization of glomerular filtration rate [6]. This raises the question as to whether such supplements should be systematically recommended for improving reno-protection in diabetic patients, with early signs of renal damage.

Methods

Results

Conclusion